Literature DB >> 24605828

Activated AKT pathway promotes establishment of endometriosis.

Tae Hoon Kim1, Yanni Yu, Lily Luo, John P Lydon, Jae-Wook Jeong, J Julie Kim.   

Abstract

The pathogenesis of endometriosis remains unclear, and relatively little is known about the mechanisms that promote establishment and survival of the disease. Previously, we demonstrated that v-akt murine thymoma viral oncogene homolog (AKT) activity was increased in endometriosis tissues and cells from ovarian endometriomas and that this increase promoted cell survival as well as decreased levels of progesterone receptor. The objective of this study was to demonstrate a role for AKT in the establishment of ectopic lesions. First, a dose-dependent inhibition of AKT in stromal cells from human ovarian endometriomas (OSIS) as well as endometrial stromal cells from disease-free patients (ESC) with the allosteric AKT inhibitor MK-2206 was demonstrated by decreased levels of phosphorylated (p)(Ser473)-AKT. Levels of the AKT target protein, p(Ser256)-forkhead box O1 were increased in OSIS cells, which decreased with MK-2206 treatment, whereas levels of p(Ser9)-glycogen synthase kinase 3β did not change in response to MK-2206. Although MK-2206 decreased viability of both OSIS and ESC in a dose-dependent manner, proliferation of OSIS cells was differentially decreased significantly compared with ESC. Next, the role of hyperactive AKT in the establishment of ectopic lesions was studied using the bigenic, PR(cre/+)Pten(f/+) heterozygous mouse. Autologous implantation of uterine tissues was performed in these mice. After 4 weeks, an average of 4 ± 0.33 lesions per Pten(f/+) mouse and 7.5 ± 0.43 lesions in the PR(cre/+)Pten(f/+) mouse were found. Histological examination of the lesions showed endometrial tissue-like morphology, which was similar in both the Pten(f/+) and PR(cre/+)Pten(f/+) mice. Treatment of mice with MK-2206 resulted in a significantly decreased number of lesions established. Immunohistochemical staining of ectopic lesions revealed decreased p(Ser473)-AKT and the proliferation marker Ki67 from MK-2206-treated mice compared with vehicle-treated mice. Furthermore, levels of FOXO1 and progesterone receptor increased in lesions of mice receiving MK-2206. These results demonstrate that heightened AKT activity plays an active role in the establishment of ectopic endometrial tissues.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24605828      PMCID: PMC3990849          DOI: 10.1210/en.2013-1951

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  32 in total

Review 1.  Endometriosis.

Authors:  Serdar E Bulun
Journal:  N Engl J Med       Date:  2009-01-15       Impact factor: 91.245

2.  MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.

Authors:  Hiroshi Hirai; Hiroshi Sootome; Yoko Nakatsuru; Katsuyoshi Miyama; Shunsuke Taguchi; Kyoko Tsujioka; Yoko Ueno; Harold Hatch; Pradip K Majumder; Bo-Sheng Pan; Hidehito Kotani
Journal:  Mol Cancer Ther       Date:  2010-06-22       Impact factor: 6.261

Review 3.  Clinical practice. Endometriosis.

Authors:  Linda C Giudice
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

4.  Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59-mediated apoptosis.

Authors:  Nikki L Neubauer; Erin C Ward; Parin Patel; Zhenxiao Lu; Irene Lee; Leen J Blok; Payman Hanifi-Moghaddam; Julian Schink; J Julie Kim
Journal:  Horm Cancer       Date:  2011-06       Impact factor: 3.869

5.  Size and spatial orientation of uterine tissue transplants on the peritoneum crucially determine the growth and cyst formation of endometriosis-like lesions in mice.

Authors:  Christina Körbel; Michael D Menger; Matthias W Laschke
Journal:  Hum Reprod       Date:  2010-08-06       Impact factor: 6.918

6.  17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaB-dependent pathway.

Authors:  Hui Zhang; Xingbo Zhao; Shu Liu; Jijun Li; Zeqing Wen; Mingjiang Li
Journal:  Mol Cell Endocrinol       Date:  2009-11-22       Impact factor: 4.102

7.  Aberrant gene expression profile in a mouse model of endometriosis mirrors that observed in women.

Authors:  Katherine E Pelch; Amy L Schroder; Paul A Kimball; Kathy L Sharpe-Timms; J Wade Davis; Susan C Nagel
Journal:  Fertil Steril       Date:  2009-05-26       Impact factor: 7.329

8.  Increased mitogen-activated protein kinase kinase/extracellularly regulated kinase activity in human endometrial stromal fibroblasts of women with endometriosis reduces 3',5'-cyclic adenosine 5'-monophosphate inhibition of cyclin D1.

Authors:  Michael C Velarde; Lusine Aghajanova; Camran R Nezhat; Linda C Giudice
Journal:  Endocrinology       Date:  2009-07-09       Impact factor: 4.736

9.  Progestins activate the AKT pathway in leiomyoma cells and promote survival.

Authors:  Anna V Hoekstra; Elizabeth C Sefton; Emily Berry; Zhenxiao Lu; Jennifer Hardt; Erica Marsh; Ping Yin; Jon Clardy; Debabrata Chakravarti; Serdar Bulun; J Julie Kim
Journal:  J Clin Endocrinol Metab       Date:  2009-02-24       Impact factor: 5.958

10.  Differential regulation of Akt phosphorylation in endometriosis.

Authors:  Ozgur Cinar; Yasemin Seval; Yesim H Uz; Hakan Cakmak; Murat Ulukus; Umit A Kayisli; Aydin Arici
Journal:  Reprod Biomed Online       Date:  2009-12       Impact factor: 3.828

View more
  26 in total

1.  Dual inhibition of ERK1/2 and AKT pathways is required to suppress the growth and survival of endometriotic cells and lesions.

Authors:  Joe A Arosh; Sakhila K Banu
Journal:  Mol Cell Endocrinol       Date:  2018-12-20       Impact factor: 4.102

2.  Influence of Cancer-Associated Endometrial Stromal Cells on Hormone-Driven Endometrial Tumor Growth.

Authors:  M J Pineda; Z Lu; D Cao; J J Kim
Journal:  Horm Cancer       Date:  2015-05-15       Impact factor: 3.869

3.  The allosteric AKT inhibitor, MK2206, decreases tumor growth and invasion in patient derived xenografts of endometrial cancer.

Authors:  Abigail Winder; Kenji Unno; Yanni Yu; John Lurain; J Julie Kim
Journal:  Cancer Biol Ther       Date:  2017-11-27       Impact factor: 4.742

4.  Regulation of AKT Signaling in Mouse Uterus.

Authors:  Vijay K Sirohi; Theresa I Medrano; Ana M Mesa; Athilakshmi Kannan; Indrani C Bagchi; Paul S Cooke
Journal:  Endocrinology       Date:  2022-01-01       Impact factor: 4.736

5.  A Mouse Model of Endometriosis with Nanoparticle Labeling for In Vivo Photoacoustic Imaging.

Authors:  Ryan M Marquardt; Md Nafiujjaman; Tae Hoon Kim; Seock-Jin Chung; Kay Hadrick; Taeho Kim; Jae-Wook Jeong
Journal:  Reprod Sci       Date:  2022-05-31       Impact factor: 2.924

Review 6.  Strategies for modelling endometrial diseases.

Authors:  Alina R Murphy; Hannes Campo; J Julie Kim
Journal:  Nat Rev Endocrinol       Date:  2022-09-01       Impact factor: 47.564

Review 7.  Autophagy in endometriosis.

Authors:  Hui-Li Yang; Jie Mei; Kai-Kai Chang; Wen-Jie Zhou; Li-Qing Huang; Ming-Qing Li
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 8.  Influence of AKT on progesterone action in endometrial diseases.

Authors:  Irene I Lee; J Julie Kim
Journal:  Biol Reprod       Date:  2014-08-06       Impact factor: 4.285

9.  Genetic and epigenetic changes in the eutopic endometrium of women with endometriosis: association with decreased endometrial αvβ3 integrin expression.

Authors:  Niraj R Joshi; Hamid-Reza Kohan-Ghadr; Damian S Roqueiro; Jung Yoon Yoo; Karenne Fru; Eli Hestermann; Lingwen Yuan; Shuk-Mei Ho; Jae-Wook Jeong; Steven L Young; Bruce A Lessey; Asgerally T Fazleabas
Journal:  Mol Hum Reprod       Date:  2021-05-29       Impact factor: 4.025

10.  Interleukin-6 (IL-6) Activates the NOTCH1 Signaling Pathway Through E-Proteins in Endometriotic Lesions.

Authors:  Yong Song; Ren-Wei Su; Niraj R Joshi; Tae Hoon Kim; Bruce A Lessey; Jae-Wook Jeong; Asgerally T Fazleabas
Journal:  J Clin Endocrinol Metab       Date:  2020-05-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.